TLDR The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.
The document acknowledges an error in a previously published article titled "Pimecrolimus. Pharmacology and preclinical studies" in the journal Piel, specifically in the caption of figure 8. The error pertained to the incorrect naming of a drug; where "tacrolimus" was mentioned, it should have been "pimecrolimus." The corrected figure caption is provided, indicating that pimecrolimus, not tacrolimus, preferentially distributes in the skin according to pharmacokinetic data from an experimental study involving oral doses of 25 mg/kg in rats, with concentrations measured 6 hours after the second dose. The figure shows the tissue concentration ratio of pimecrolimus to tacrolimus.
76 citations
,
October 2019 in “Dermatology and Therapy” Atopic dermatitis is common in developing countries, but many patients receive poor care due to inconsistent guidelines and lack of resources.
4 citations
,
September 2014 in “Elsevier eBooks” Use some skin medications with caution during pregnancy; avoid strong steroids, certain eczema treatments, and systemic retinoids, but many topical treatments and nasal sprays are safe.
159 citations
,
March 2014 in “Journal of The American Academy of Dermatology” Some skin medications are safe during pregnancy and breastfeeding, but others can harm the baby and should be avoided.
122 citations
,
December 2022 in “International Journal of Molecular Sciences” Nanoparticles improve skin treatment but need more research on safety and effectiveness.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.